Drug Type Small molecule drug |
Synonyms Enarodustat (JAN), 恩那度司他, JTZ-951 + [4] |
Target |
Mechanism HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (25 Sep 2020), |
Regulation- |
Molecular FormulaC17H17ClN4O4 |
InChIKeyBPZAJOSLAXGKFI-UHFFFAOYSA-N |
CAS Registry1262131-60-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
chronic renal failure anemia | KR | 17 Nov 2022 | |
Anemia of renal disease | JP | 25 Sep 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia in chronic kidney disease | Phase 1 | US | 01 May 2013 | |
Kidney Failure, Chronic | Phase 1 | US | 01 May 2013 |
Not Applicable | Anemia in chronic kidney disease Maintenance hemoglobin | Erythropoiesis Stimulating Agents (ESAs) | iv iron ... View more | 40 | oglneydbtj(ftdxtzofnm) = The results of reticulocyte count, hematocrit level and red blood cells in terms of changes from baseline at week 8 were similar to that in hemoglobin hmrnrtxzyn (xjutjoaibb ) View more | Positive | 21 May 2015 | ||
JTZ-951 3 mg | |||||||
Not Applicable | Anemia in chronic kidney disease hemoglobin | erythropoietin | 22 | pmpnvzoqqj(gfrigyyxor) = The results of reticulocyte count, hematocrit level and red blood cells in terms of changes from baseline at Week 6 were similar to that in hemoglobin rwzrkjlqdq (pffomaukja ) View more | Positive | 21 May 2015 | ||
Phase 1 | hemoglobin | transferrin saturation | ferritin ... View more | - | JTZ-951 2 mg | bcvkgyzzuv(aeqgvjynyt) = kkqfnlrsfk pnnjebfozx (dkbdtlcgbw ) | Positive | 21 May 2015 | |
JTZ-951 10 mg | bcvkgyzzuv(aeqgvjynyt) = jkxdibudwn pnnjebfozx (dkbdtlcgbw, -0.7 to 2.3) |